Although BH3 mimetics and BTK inhibitors in combination with Rituximab, Cyclophosphamide, Hydroxydaunorubicin, Oncovin, and Prednisone (R-CHOP) have shown additional benefit [8, 9], this does not hold true for all patients and relapse remains a problem, especially in ABC-DLBCL and other high-risk molecular subtypes. The gene discussed is BTK; the disease is aneurysmal bone cyst.